Trading Signals: VBIV Stock Price Prediction and Forecast (Thu. May. 4, 2006 - Fri. Jul. 24, 2020)(VBI Vaccines Inc)
| VBIV latest price $16.6600 (-11.05%) ($16.5500 - $17.7800) on Tue. Jul. 6, 2010. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.74% (three month average) | RSI | 45 | Latest Price | $16.6600(-11.05%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | VBIV declines -2.9% a day on average for past five trading days. | Weekly Trend | VBIV advances 1.2% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support VBIV advance at 0% a week (0% probability) GLD(19%) OIH(12%) VWO(12%) EEM(11%) EWG(11%) | Factors Impacting VBIV price | VBIV will decline at least -2.37% in a week (0% probabilities). TLT(-5%) TIP(1%) SHY(3%) LQD(3%) XLU(4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.37% (StdDev 4.74%) | Hourly BBV | 0 () | Intraday Trend | -5.4% | | | |
|
1 - 5 Day Possible Target | $9.89(-40.64%) | Resistance Level | $18.56 | 5 Day Moving Average | $18.32(-9.06%) | 10 Day Moving Average | $18.51(-9.99%) | 20 Day Moving Average | $18.56(-10.24%) | To recent high | -45.7% | To recent low | 0% | Market Cap | $3.843b | | | | VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.VBI's COVID-19 vaccine candidate, VBI-2901, is noteworthy because it could potentially also confer immunity to other coronaviruses which cause diseases like MERS (Middle Eastern Respiratory Syndrome). More importantly, VBI appears to be facing a bottleneck either in its preclinical research or its vaccine manufacturing capabilities. VBI doesn't expect to have the necessary clinical study materials assembled for its COVID-19 vaccine trial before the fourth quarter, meaning that it's roughly a quarter behind Vaxart in the development process. |